Ten stocks boasted strong double- to triple-digit gains last week, outperforming a mostly optimistic US market amid US and Iran’s efforts for a peace deal.

Notably, investors poured funds into industries with promising growth prospects, namely semiconductor and quantum computing, while some favored pharmaceutical players thanks to progress on their pipeline drugs.

In this article, we name the 10 best performers last week and detail the reasons behind their gains.

To come up with the list, we only considered the stocks with a $2 billion market capitalization and based their rankings on the percentage growth in their share prices on April 10 and 17, 2026.

10. Travere Therapeutics Inc. (NASDAQ:TVTX)

Travere Therapeutics grew its share prices by 40.78 percent week-on-week, as investors increased their positions after securing the approval of the Food and Drug Administration (FDA) for its kidney disease treatment, Filspari.

In a statement earlier in the week, Travere Therapeutics Inc. (NASDAQ:TVTX) said that the FDA has given the green light for Filspari to treat patients aged 8 and above who are suffering from focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. It is the only medicine approved by the FDA to treat FSGS.

The approval followed the successful phase 3 study of the drug, which saw a 46 percent reduction in proteinuria at week 108, as compared with the 30 percent for those treated with the maximum labeled dose of irbesartan.

Travere Therapeutics Inc. (NASDAQ:TVTX) noted that Filspari demonstrated even greater improvements in patients without nephrotic syndrome, versus the maximum labeled dose of irbesartan across proteinuria and eGFR.

“This approval reflects years of perseverance and our belief that those living with FSGS deserve better. It also builds on our leadership and progress in rare kidney diseases, expanding Filspari’s potential reach to more than 100,000 people in the US with FSGS and IgAN (IgA nephropathy) who need better treatment options,” said Travere Therapeutics Inc. (NASDAQ:TVTX) President and CEO Eric Dube.

“Filspari will be available for nephrologists to immediately prescribe to individuals with FSGS. We are profoundly grateful to the patients, caregivers, investigators, healthcare providers, regulators and advocates who made this moment possible,” he noted.

9. Spyre Therapeutics Inc. (NASDAQ:SYRE)

Spyre Therapeutics grew its share prices by 42.3 percent week-on-week, as investors took heart from the “best-in-class” potential of its therapy candidate for ulcerative colitis (UC).

In an updated report earlier in the week, Spyre Therapeutics Inc. (NASDAQ:SYRE) said that its treatment candidate, SPY001, saw a clinical remission rate of 40 percent at 12 weeks versus Entyvio’s 27 percent at 14 weeks.

The drug also achieved a 51 percent improvement in endoscopic versus its competitor’s 41 percent at six weeks.

Following the news, investment firm BTIG upgraded its price target for Spyre Therapeutics Inc. (NASDAQ:SYRE) to $98 from $70 previously, while maintaining a “buy” recommendation.

BTIG also raised to 80 percent its expectations for SPY001 combinations to succeed, as well as penetration rates for UC and Crohn’s disease to 30 and 20 percent, respectively.

In other news, Spyre Therapeutics Inc. (NASDAQ:SYRE) kicked off a $300 million share sale in line with plans to raise funds to support its pipeline programs.

It also granted its underwriters a $45 million overallotment option at the same price for 30 days from the public offering date.

8. Hims & Hers Health Inc. (NYSE:HIMS)

Hims & Hers saw its share prices jump by 48.3 percent week-on-week as investors positioned portfolios ahead of the results of its earnings performance for the first quarter of the year, supported by optimism over its rekindled partnership with Novo Nordisk.

In an updated report, Hims & Hers Health Inc. (NYSE:HIMS) said that it is scheduled to release the results of its earnings performance after market close on May 11, 2026. A conference call will be held to elaborate on the results.

For the period, the company expects to grow its year-on-year revenues by 2.4 percent to 6.7 percent to a range of $600 million to $625 million, versus $586 million in the same period a year earlier.

Adjusted EBITDA is projected at a range of $35 million to $55 million, or a decline of 40 percent to 61.6 percent from the $91.1 million in the same comparable period.

Investors are also expected to watch for Hims & Hers Health Inc.’s (NYSE:HIMS) outlook for the second quarter of the year after it renewed its partnership with Novo Nordisk for the sale of the latter’s Wegovy and Ozempic on the HIMS platform. The partnership initially began last year but was terminated a month later after Novo accused Hims of “failing to adhere to the law” by continuing to sell its compounded GLP-1 drugs.

In the newly inked contract, Hims & Hers Health Inc. (NYSE:HIMS) committed to sell only the FDA-approved weight loss drugs, while the compounded GLP-1 versions will be offered only in cases where the needs of the customers cannot be met using the FDA-approved version, and if a provider determines that a compounded product is clinically necessary.

7. NextNav Inc. (NASDAQ:NN)

NextNav rallied by 49.4 percent week-on-week, as investors took heart from a flurry of developments, including analyst expectations that it could become an acquisition target.

In a market note earlier in the week, Oppenheimer said that NextNav Inc. (NASDAQ:NN) could be an acquisition target on expectations that it would secure the approval of the Federal Communications Commission (FCC) for its spectrum rebranding plans.

If approved, the listed firm is expected to receive an additional 1MHz of spectrum, giving it continuous 15MHz in the lower 900MHz band for a total of 5.1 billion MHz-POPs.

The additional spectrum means that NextNav Inc. (NASDAQ:NN) would be able to serve a larger number of people more effectively.

In line with the projections, Oppenheimer upgraded NextNav Inc. (NASDAQ:NN) to “outperform” from “perform” previously, while assigning a $25 price target, or a 9.5 percent upside potential from its latest closing price. Friday also marked its seventh straight day of gains.

In other developments, NextNav Inc. (NASDAQ:NN) last Thursday secured the FCC approval to conduct a field test to validate the coexistence between its proposed 5G operations and the licensed operations of railroad automatic equipment identification systems in Pueblo, Colorado.

6. D-Wave Quantum Inc. (NYSE:QBTS)

D-Wave Quantum soared by 52.2 percent week-on-week amid a combination of broader market optimism and Nvidia Corp.’s launch of two new products aimed at solving the challenges in the quantum computing industry.

Earlier in the week, D-Wave Quantum Computing Inc. (NYSE:QBTS) climbed alongside its counterparts Rigetti, IonQ, and Infleqtion, among others, following Nvidia’s launch of a new AI-powered workflow designed to correct quantum systems’ biggest problems.

Called the Ising Calibration and Ising Decoding, Nvidia said that the two model domains can both target the fundamental challenges in quantum computing.

Ising Calibration is a vision-language model for automating QPU calibration tasks capable of understanding quantum computing scientific experiment output and how it compares to expected trends, while Ising Decoding consists of two 3D CNN models for demanding decoding needed during quantum error correction.

Investors took the development positively, sparking appetite for key players, including D-Wave Quantum Computing Inc. (NYSE:QBTS), as it validated the increasing importance of the quantum sector after tech executives last year said that they deem the industry useful only decades away.

Click to continue reading and see the other 5 Stocks With Monster Returns.

Disclosure: None. Follow Insider Monkey on Google News.